| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive system disease | Under Review | Human, Rat, Mouse | 0.12 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.2 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.29 | KE:520 | Decreased sperm quantity or quality in the adult, Decreased fertility |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| AOP:111 | Decrease in androgen receptor activity leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus | 0.2 | KE:754 | Increased, Luteinizing hormone (LH) |
| AOP:120 | Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus, Mus musculus | 0.4 | KE:791 | Increased, Leutinizing hormone (LH) |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.17 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine system disease | - | Human, Rat | 0.12 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.18 | KE:10037 | Downregulation of tyrosinase and hexokinase genes | |
| KE:592 | Reduced, survival | ||||||
| AOP:348 | Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory | Unclassified | Under Development | Fish | 0.2 | KE:1758 | Impaired, Spermatogenesis |
| AOP:349 | Inhibition of 11β-hydroxylase leading to decresed population trajectory | Unclassified | Under Development | Fish | 0.12 | KE:1798 | Decreased spermatogenesis |
| AOP:444 | Ionizing radiation leads to reduced reproduction in Eisenia fetida via reduced spermatogenesis and cocoon hatchability | Unclassified | - | 0.11 | KE:1798 | Decreased spermatogenesis | |
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.11 | KE:854 | Alterations, Cellular proliferation / hyperplasia | |
| AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | Zebrafish | 0.1 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.17 | KE:2195 | Increase, CNS Neural cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | Zebrafish, Medaka, Gallus gallus | 0.2 | KE:947 | Increase, Early Life Stage Mortality |
| AOP:91 | Sodium channel inhibition leading to reduced survival | Unclassified | - | Medaka, Gammarus pulex, Hydra | 0.17 | KE:592 | Reduced, survival |
| AOP:95 | Ether-a-go-go (ERG) voltage-gated potassium channel inhibition leading to reduced survival | Unclassified | - | 0.17 | KE:592 | Reduced, survival | |
| AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | Zebrafish | 0.14 | KE:636 | Decreased, survival |
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.17 | KE:773 | Increase, Endometrial adenocarcinomas |
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.25 | KE:885 | Increase, Cancer |
| AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | Chicken, Zebrafish, Mouse, Rattus norvegicus | 0.14 | KE:947 | Increase, Early Life Stage Mortality |
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.17 | KE:1506 | Testicular atrophy |
| AOP:242 | Inhibition of lysyl oxidase leading to enhanced chronic fish toxicity | Unclassified | - | Fish | 0.12 | KE:636 | Decreased, survival |
| AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | Rattus rattus, Mus musculus | 0.11 | KE:1193 | N/A, Breast Cancer |
| AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic disease; Thoracic disease; Cancer | Under Development | 0.11 | KE:1193 | N/A, Breast Cancer | |
| AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive system disease | - | 0.2 | KE:1757 | Reduce, Sperm count | |
| AOP:323 | PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone | Unclassified | - | Teleost fish | 0.33 | KE:1758 | Impaired, Spermatogenesis |
| KE:2147 | Decreased, Viable Offspring | ||||||
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.22 | KE:1982 | metastatic breast cancer |
| KE:1971 | Increased, tumor growth | ||||||
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.1 | KE:1982 | metastatic breast cancer |
| AOP:455 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced impeded craniofacial development | Musculoskeletal system disease | Under Review | Zebrafish, Mouse, Human, Sebastiscus marmoratus, Salmo salar, Chicken | 0.17 | KE:947 | Increase, Early Life Stage Mortality |
| AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | Zebrafish, Mouse, Human, Chicken | 0.17 | KE:947 | Increase, Early Life Stage Mortality |
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.2 | KE:885 | Increase, Cancer |
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.2 | KE:885 | Increase, Cancer |
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.43 | KE:2206 | Increased, histomorphological alteration of testis |
| KE:1758 | Impaired, Spermatogenesis | ||||||
| KE:2147 | Decreased, Viable Offspring | ||||||
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.17 | KE:885 | Increase, Cancer |
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.